



MediWound
Investor Relations Department
42 Yarkon St
Yavne 81227
Israel

[Visit IR website](#)
[Sign-up for email alerts](#)

NASDAQ: MDWD

Last Trade:	6.20
Trade Time:	10:17 AM ET Aug 17, 2017
Change:	-0.10 (1.587%)
Day Range	6.20 - 6.25
52-Week Range	4.25 - 8.58
Volume	4,113

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

MediWound is a fully integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology that address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. MediWound's first innovative biopharmaceutical product, NexoBrid, received marketing authorization from the European Medicines Agency for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in Europe. NexoBrid represents a ... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Aug 3, 2017

[MediWound Reports Second Quarter 2017 Financial Results](#)

Jul 28, 2017

[MediWound to Host Second Quarter 2017 Financial Results Conference Call on August 3, 2017 at 8:30 a.m. Eastern Time](#)

Jul 19, 2017

[BARDA Upsizes Contract with MediWound and Exercises Option to Fund Further NexoBrid® Indications](#)

Jun 23, 2017

[BARDA Gives Notice of Intent to Exercise First Contract Option to Further Fund MediWound's NexoBrid® Development](#)

Jun 16, 2017

[Independent Study in Germany Shows NexoBrid® Reduces Average Burn Treatment Costs by nearly 30% Versus Standard of Care](#)

Financials [\[View all \]](#)

[Second Quarter Financial Results](#)

Feb 21, 2017

[Annual Report for Foreign Private Issuers \(20-F\)](#)